Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 110 results for anticoagulation

  1. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)

    This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer.

  2. Atrial fibrillation: diagnosis and management (NG196)

    This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.

  3. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

  4. Atrial fibrillation (QS93)

    This quality standard covers identifying and managing atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  5. Venous thromboembolism in adults (QS201)

    This quality standard covers reducing the risk of venous thromboembolism (VTE) in people aged 16 and over who are in hospital. It also covers diagnosing and treating VTE in all people aged 18 and over. It describes high-quality care in priority areas for improvement.

  6. Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]

    In development [GID-TA11472] Expected publication date: 18 December 2024

  7. Intrapartum care for women with existing medical conditions or obstetric complications and their babies (NG121)

    This guideline covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. The guideline also covers women who have had no antenatal care. It aims to improve experiences and outcomes for women and their babies.

  8. Stroke Prevention in Atrial Fibrillation (AF) Protect and Perfect – Optimising anticoagulation treatment

    clinicians to Protect and Protect patients diagnosed with AF on appropriate anticoagulation therapy in line with NICE guidance, thereby...

  9. microINR for anticoagulation therapy (MIB257)

    NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .

  10. A programme to introduce annual GP review for patients on warfarin with atrial fibrillation who display poor anticoagulation control

    Fibrillation (2014) and subsequent Quality Standard (2015) prompted the Anticoagulation Service within City Health Care Partnership to...

  11. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.

  12. Blood transfusion (NG24)

    This guideline covers the assessment for and management of blood transfusions in adults, young people and children over 1 year old. It covers the general principles of blood transfusion, but does not make recommendations relating to specific conditions.

  13. Improving anticoagulation in patients with atrial fibrillation using the GRASP AF audit tool (part of the GRASP suite of tools delivered by PRIMIS in partnership with NHS England)

    being at high risk of stroke, based on the relevant recommendations for anticoagulation in NICE guidance for AF (NG196). This example...

  14. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

    This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.

  15. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis and preventing a pulmonary embolism or another deep vein thrombosis in adults.